Merck
  • Home
  • Search Results
  • Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan.

Antibody responses to a panel of Plasmodium falciparum malaria blood-stage antigens in relation to clinical disease outcome in Sudan.

Vaccine (2008-11-04)
Nnaemeka C Iriemenam, Atif H Khirelsied, Amre Nasr, Gehad ElGhazali, Haider A Giha, Thoraya M Elhassan A-Elgadir, Ahmed A Agab-Aldour, Scott M Montgomery, Robin F Anders, Michael Theisen, Marita Troye-Blomberg, Mustafa I Elbashir, Klavs Berzins
ABSTRACT

Despite many intervention programmes aimed at curtailing the scourge, malaria remains a formidable problem of human health. Immunity to asexual blood-stage of Plasmodium falciparum malaria is thought to be associated with protective antibodies of certain immunoglobulin classes and subclasses. We have analysed immunoglobulin G profiles to six leading blood-stage antigens in relation to clinical malaria outcome in a hospital-based study in Sudan. Our results revealed a linear association with anti-AMA-1-IgG1 antibodies in children <5 years and reduced risk of severe malaria, while the responses of the IgG3 antibodies against MSP-2, MSP-3, GLURP in individuals above 5 years were bi-modal. A dominance of IgG3 antibodies in >5 years was also observed. In the final combined model, the highest levels of IgG1 antibodies to AMA-1, GLURP-R0, and the highest levels of IgG3 antibodies to 3D7 MSP-2 were independently associated with protection from clinical malaria. The study provides further support for the potential importance of the studied merozoite vaccine candidate antigens as targets for parasite neutralizing antibody responses of the IgG1 and IgG3 subclasses.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-Human IgG4−Biotin antibody, Mouse monoclonal, clone HP-6025, purified from hybridoma cell culture